Index -
P/E -
EPS (ttm) -0.72
Insider Own 55.09%
Shs Outstand 13.54M
Perf Week 2.53%
Market Cap 68.83M
Forward P/E -
EPS next Y -0.34
Insider Trans 0.34%
Shs Float 6.10M
Perf Month -7.40%
Income -9.73M
PEG -
EPS next Q -0.16
Inst Own 18.93%
Short Float 0.95%
Perf Quarter -18.44%
Sales 49.22M
P/S 1.40
EPS this Y -93.14%
Inst Trans -0.67%
Short Ratio 12.82
Perf Half Y -20.74%
Book/sh -0.15
P/B -
EPS next Y 46.03%
ROA -30.91%
Short Interest 0.06M
Perf Year 9.16%
Cash/sh 0.33
P/C 15.40
EPS next 5Y 15.00%
ROE -388.65%
52W Range 4.17 - 7.32
Perf YTD -9.87%
Dividend Est. -
P/FCF -
EPS past 5Y -24.83%
ROI -222.15%
52W High -30.81%
Beta 0.38
Dividend TTM -
Quick Ratio 0.60
Sales past 5Y 21.90%
Gross Margin 40.09%
52W Low 21.46%
ATR (14) 0.21
Dividend Ex-Date -
Current Ratio 0.60
EPS Y/Y TTM -212.30%
Oper. Margin -17.87%
RSI (14) 45.91
Volatility 2.49% 3.54%
Employees 230
Debt/Eq -
Sales Y/Y TTM -8.29%
Profit Margin -19.76%
Recom 3.00
Target Price 6.00
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q -3.45%
Payout -
Rel Volume 0.26
Prev Close 5.03
Sales Surprise -11.11%
EPS Surprise -166.67%
Sales Q/Q -5.90%
Earnings Mar 12 AMC
Avg Volume 4.53K
Price 5.07
SMA20 -0.22%
SMA50 -7.94%
SMA200 -13.86%
Trades
Volume 1,206
Change 0.70%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-18-19 Initiated
The Benchmark Company
Speculative Buy
Mar-19-24 08:28AM
Mar-12-24 04:30PM
Mar-07-24 09:00AM
Mar-06-24 04:35PM
Dec-14-23 08:22AM
09:54PM
Loading…
Dec-12-23 09:54PM
04:00PM
Dec-04-23 04:30PM
Nov-02-23 08:30AM
Oct-17-23 08:30AM
Sep-13-23 04:00PM
Sep-11-23 04:00PM
Aug-22-23 08:30AM
Aug-01-23 08:45AM
Jul-24-23 04:00PM
04:00PM
Loading…
Jul-20-23 04:00PM
Apr-17-23 08:30AM
Apr-05-23 09:50AM
Mar-15-23 03:50PM
Mar-13-23 08:30AM
Dec-16-22 08:48AM
Dec-13-22 04:00PM
Dec-09-22 04:30PM
Sep-08-22 04:00PM
Sep-06-22 04:00PM
Aug-15-22 08:08AM
Jul-23-22 09:57AM
Jul-21-22 04:00PM
Jul-14-22 04:00PM
Jun-13-22 06:30AM
08:30AM
Loading…
May-31-22 08:30AM
May-03-22 08:30AM
May-02-22 01:16PM
Mar-15-22 04:45PM
Mar-11-22 08:30AM
Mar-07-22 01:10PM
Feb-15-22 08:30AM
Jan-20-22 08:30AM
Jan-04-22 08:30AM
05:07AM
Dec-13-21 04:20PM
Dec-06-21 09:20AM
Nov-05-21 08:24AM
Oct-20-21 10:25AM
Sep-13-21 04:00PM
Sep-06-21 03:00PM
07:09AM
Sep-02-21 04:30PM
Jul-26-21 08:30AM
Jul-22-21 08:00AM
Jul-14-21 08:30AM
Jul-08-21 03:06AM
Jun-15-21 09:00AM
Apr-29-21 03:31AM
Apr-16-21 12:00PM
Mar-16-21 10:52AM
Mar-15-21 02:13AM
(Simply Wall St.) +15.31%
Mar-11-21 04:00PM
02:30PM
Mar-05-21 08:30AM
Mar-04-21 12:30PM
Feb-22-21 09:00AM
Jan-29-21 12:24AM
Jan-19-21 09:00AM
Jan-05-21 08:30AM
Dec-15-20 12:22AM
Dec-14-20 04:00PM
Dec-07-20 04:00PM
Nov-16-20 04:40PM
Nov-11-20 09:00AM
Oct-31-20 10:08AM
Sep-16-20 07:27AM
Sep-14-20 04:00PM
Sep-08-20 04:30PM
Jul-30-20 07:21AM
Jul-27-20 04:01PM
Jul-22-20 08:00AM
Jul-15-20 03:55PM
Jun-17-20 09:37AM
May-27-20 07:05AM
Apr-28-20 09:50AM
Apr-27-20 07:20AM
Mar-28-20 09:23AM
Mar-16-20 09:35AM
Mar-12-20 04:17PM
Mar-10-20 08:30AM
Feb-26-20 09:32AM
Feb-18-20 05:44AM
Feb-05-20 09:23AM
Jan-29-20 09:00AM
Jan-17-20 09:34AM
Jan-13-20 06:07AM
Dec-24-19 09:37AM
Dec-16-19 04:00PM
Dec-09-19 08:30AM
Dec-08-19 08:59AM
Dec-04-19 08:36AM
Nov-14-19 08:53AM
Nov-13-19 05:00PM
Nov-12-19 07:27AM
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mendelson Daniel Newman Director Jan 12 '24 Buy 6.50 1,000 6,500 198,625 Jan 16 11:45 AM Mendelson Daniel Newman Director Jan 11 '24 Buy 6.27 2,000 12,540 197,625 Jan 12 12:47 PM Mendelson Daniel Newman Director Jan 10 '24 Buy 6.31 2,944 18,577 195,625 Jan 11 10:57 AM Mendelson Daniel Newman Director Jan 09 '24 Buy 6.25 3,000 18,750 192,681 Jan 10 08:57 AM Mendelson Daniel Newman Director Jan 08 '24 Buy 6.15 1,000 6,150 189,681 Jan 09 09:08 AM Mendelson Daniel Newman Director Jan 05 '24 Buy 6.09 2,000 12,180 188,681 Jan 08 03:11 PM Mendelson Daniel Newman Director Jan 04 '24 Buy 6.12 3,000 18,360 186,681 Jan 08 02:54 PM Mendelson Daniel Newman Director Jan 03 '24 Buy 5.83 500 2,915 183,681 Jan 04 01:37 PM Mendelson Daniel Newman Director Dec 21 '23 Buy 4.92 2,500 12,300 183,181 Dec 26 11:48 AM Mendelson Daniel Newman Director Dec 20 '23 Buy 4.82 2,100 10,122 180,681 Dec 21 02:31 PM Mendelson Daniel Newman Director Dec 19 '23 Buy 4.75 5,000 23,750 178,581 Dec 20 09:48 AM ACKERMAN JOEL Director Oct 17 '23 Option Exercise 2.10 114,552 240,559 856,997 Jan 05 03:52 PM Mendelson Daniel Newman Director Oct 11 '23 Buy 6.40 5,000 32,000 163,081 Oct 13 12:48 PM Mendelson Daniel Newman Director Oct 10 '23 Buy 6.41 1,100 7,051 158,081 Oct 11 09:45 AM Mendelson Daniel Newman Director Oct 06 '23 Buy 6.48 1,530 9,914 156,981 Oct 10 10:02 AM Mendelson Daniel Newman Director Oct 05 '23 Buy 6.47 2,000 12,940 155,451 Oct 06 07:10 AM Mendelson Daniel Newman Director Oct 04 '23 Buy 6.40 5,000 32,000 153,451 Oct 04 05:30 PM Mendelson Daniel Newman Director Oct 03 '23 Buy 6.30 2,500 15,750 148,451 Oct 04 05:31 PM Mendelson Daniel Newman Director Sep 29 '23 Buy 6.16 4,000 24,640 173,581 Oct 16 09:53 AM Mendelson Daniel Newman Director Sep 28 '23 Buy 6.22 5,000 31,100 169,581 Oct 16 09:52 AM Mendelson Daniel Newman Director Sep 27 '23 Buy 5.95 1,500 8,925 164,581 Oct 16 09:51 AM Mendelson Daniel Newman Director Sep 26 '23 Buy 5.65 5,000 28,250 145,951 Sep 27 09:56 AM Mendelson Daniel Newman Director Sep 22 '23 Buy 5.50 3,812 20,966 140,951 Sep 25 02:59 PM Mendelson Daniel Newman Director Sep 21 '23 Buy 5.51 5,000 27,550 137,139 Sep 25 02:59 PM Mendelson Daniel Newman Director Sep 20 '23 Buy 5.51 4,018 22,139 132,139 Sep 25 02:59 PM Mendelson Daniel Newman Director Sep 19 '23 Buy 5.28 5,000 26,400 128,121 Sep 25 03:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite